MARKET

BNTC

BNTC

Benitec Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.718
-0.162
-4.18%
Opening 11:24 07/23 EDT
OPEN
3.770
PREV CLOSE
3.880
HIGH
3.850
LOW
3.710
VOLUME
26.84K
TURNOVER
--
52 WEEK HIGH
10.49
52 WEEK LOW
2.300
MARKET CAP
29.20M
P/E (TTM)
-0.0229
1D
5D
1M
3M
1Y
5Y
Is Benitec Biopharma (NASDAQ:BNTC) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 05/31 05:54
77 Biggest Movers From Yesterday
Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped 23.6% to close at $9.52.
Benzinga · 05/14 09:19
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) jumped 38.7% to $4.0901 after the company said it has acquired a premier health insurance agency, J.P. Kush and Associates, Inc.
Benzinga · 05/13 16:05
AMC, OCGN, SONO and HRTX among premarket gainers
Palisade Bio (PALI) +36% on FDA's fast track designation for LB1148.Fuel Tech (FTEK) +21% on Q1 results.Lianluo Smart (LLIT) +20%.Celyad Oncology SA (CYAD) +20%.Vertex Energy (VTNR) +18% on Q1 results.InnSuites Hospitality Trust (IHT)
Seekingalpha · 05/13 12:23
26 Stocks Moving in Thursday's Pre-Market Session
Gainers Fuel Tech, Inc. (NASDAQ: FTEK) shares rose 26.3% to $2.45 in pre-market trading after the company reported upbeat results for its first quarter on Wednesday.
Benzinga · 05/13 11:01
Pfizer Internal Target Is For 3B Doses Of COVID-19 Vaccine In 2021
-Reuters
Reuters · 05/07 18:42
Mid-Afternoon Market Update: Dow Drops 90 Points; Fed Leaves Rates Unchanged
Toward the end of trading Wednesday, the Dow traded down 0.26% to 33,894.93 while the NASDAQ fell 0.01% to 14,090.09. However, the S&P gained 0.13% to 4,192.05.
Benzinga · 04/28 18:37
PINS, CLOV, ENPH and PBI among midday movers
Gainers: Brooklyn ImmunoTherapeutics (BTX) +44%.Uxin (UXIN) +25%.Ashford Hospitality Trust (AHT) +24%.Boxlight (BOXL) +21%.ADMA Biologics (ADMA) +18%.Clover Health Investments (CLOV) +16%.Unitil (UTL) +15%.Pitney Bowes (PBI) +15%.ClearSign Technologies (CL...
Seekingalpha · 04/28 16:41
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BNTC. Analyze the recent business situations of Benitec Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BNTC stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 19
Institutional Holdings: 489.35K
% Owned: 6.23%
Shares Outstanding: 7.85M
TypeInstitutionsShares
Increased
4
76.22K
New
8
238.54K
Decreased
1
54.44K
Sold Out
7
241.43K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.01%
Pharmaceuticals & Medical Research
+0.53%
Key Executives
Chairman/Director
Jerel Banks
Chief Executive Officer/Secretary
Gregory West
Chief Financial Officer
Bryan Dulhunty
Chief Scientific Officer
Michael Graham
Secretary
Oliver Kidd
Director
Kevin Buchi
Non-Executive Director
Megan Boston
Non-Executive Director
Peter Francis
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.002929
06/01/2018
About BNTC
Benitec Biopharma Inc. formerly Benitec Biopharma Limited, incorporated on April 7, 1995, a is a clinical-stage biotechnology company. The Company focused on the development of genetic medicines. The Company is developing a therapeutic technology platform that combines Ribonucleic acid (RNA) interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. The Company is using this technology, called Deoxyribonucleic acid (DNA)-directed RNA interference, or ddRNAi, to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Benitec endeavors to develop and commercialize BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy, or OPMD. The Company’s pipeline includes Oculopharyngeal Muscular Dystrophy (OPMD) Hepatitis B BB-103.

Webull offers kinds of Benitec Biopharma Inc stock information, including NASDAQ:BNTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNTC stock methods without spending real money on the virtual paper trading platform.